Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 1,034 Shares of Stock

by · The Markets Daily

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) insider Tobin Juvenal sold 1,034 shares of the business’s stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $34.20, for a total value of $35,362.80. Following the completion of the transaction, the insider owned 52,007 shares in the company, valued at approximately $1,778,639.40. This trade represents a 1.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Down 0.8%

CSTL traded down $0.27 on Thursday, reaching $35.26. The company’s stock had a trading volume of 522,288 shares, compared to its average volume of 398,525. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -53.42 and a beta of 0.99. Castle Biosciences, Inc. has a 1 year low of $17.72 and a 1 year high of $44.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. The business’s 50 day moving average is $32.08 and its 200 day moving average is $26.14.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The company had revenue of $99.86 million for the quarter, compared to the consensus estimate of $86.23 million. As a group, research analysts forecast that Castle Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Castle Biosciences

Institutional investors have recently made changes to their positions in the company. Global Retirement Partners LLC acquired a new stake in shares of Castle Biosciences during the 2nd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd boosted its holdings in Castle Biosciences by 140.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,750 shares of the company’s stock worth $68,000 after purchasing an additional 1,022 shares during the period. Quantbot Technologies LP acquired a new position in Castle Biosciences in the second quarter worth $62,000. Globeflex Capital L P bought a new stake in Castle Biosciences during the fourth quarter valued at $146,000. Finally, State of Wyoming bought a new stake in Castle Biosciences during the second quarter valued at $117,000. 92.60% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on CSTL shares. Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Wall Street Zen raised shares of Castle Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, September 26th. Roth Capital began coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 target price for the company. Robert W. Baird set a $36.00 target price on shares of Castle Biosciences in a research note on Friday, July 31st. Finally, BTIG Research upped their target price on shares of Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Castle Biosciences currently has an average rating of “Moderate Buy” and an average target price of $42.00.

View Our Latest Stock Report on CSTL

Castle Biosciences Company Profile

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians make more informed decisions about cancer diagnosis and treatment. Its products use genomic and molecular information to assess disease characteristics, patient risk and likely outcomes.

The company’s portfolio includes DecisionDx-Melanoma, which helps assess the risk of metastasis in patients with cutaneous melanoma; DecisionDx-SCC, which evaluates metastatic risk in certain patients with cutaneous squamous cell carcinoma; and MyPath Melanoma, which assists in distinguishing benign from malignant melanocytic lesions.

Featured Articles